These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 34440251)
41. Combination of Genomic Landsscape and 3D Culture Functional Assays Bridges Sarcoma Phenotype to Target and Immunotherapy. de Nigris F; Meo C; Palinski W Cells; 2023 Sep; 12(17):. PubMed ID: 37681936 [TBL] [Abstract][Full Text] [Related]
43. Emerging Targeted and Immune-Based Therapies in Sarcoma. Pollack SM; Ingham M; Spraker MB; Schwartz GK J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291 [TBL] [Abstract][Full Text] [Related]
44. Current status of immunotherapy for sarcomas. Miwa S; Nishida H; Tsuchiya H Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391 [TBL] [Abstract][Full Text] [Related]
45. Turning 'Cold' tumors 'Hot': immunotherapies in sarcoma. Rytlewski J; Milhem MM; Monga V Ann Transl Med; 2021 Jun; 9(12):1039. PubMed ID: 34277839 [TBL] [Abstract][Full Text] [Related]
46. New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype. Lim J; Poulin NM; Nielsen TO Clin Cancer Res; 2015 Nov; 21(21):4753-9. PubMed ID: 26330427 [TBL] [Abstract][Full Text] [Related]
47. The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers. Liang J; Chen D; Chen L; She X; Zhang H; Xiao Y Future Oncol; 2020 Jun; 16(17):1211-1223. PubMed ID: 32396026 [TBL] [Abstract][Full Text] [Related]
48. Immunotherapy of Childhood Sarcomas. Roberts SS; Chou AJ; Cheung NK Front Oncol; 2015; 5():181. PubMed ID: 26301204 [TBL] [Abstract][Full Text] [Related]
54. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy. Ni K; Luo T; Nash GT; Lin W Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760 [TBL] [Abstract][Full Text] [Related]
56. Cancer Immunotherapy: Beyond Checkpoint Blockade. Dougan M; Dranoff G; Dougan SK Annu Rev Cancer Biol; 2019 Mar; 3():55-75. PubMed ID: 37539076 [TBL] [Abstract][Full Text] [Related]
57. Recent advances and application of PD-1 blockade in sarcoma. Zuo W; Zhao L Onco Targets Ther; 2019; 12():6887-6896. PubMed ID: 31692518 [TBL] [Abstract][Full Text] [Related]
58. Is immunotherapy in the future of therapeutic management of sarcomas? Clemente O; Ottaiano A; Di Lorenzo G; Bracigliano A; Lamia S; Cannella L; Pizzolorusso A; Di Marzo M; Santorsola M; De Chiara A; Fazioli F; Tafuto S J Transl Med; 2021 Apr; 19(1):173. PubMed ID: 33902630 [TBL] [Abstract][Full Text] [Related]
59. Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer. Kudelova E; Smolar M; Holubekova V; Hornakova A; Dvorska D; Lucansky V; Koklesova L; Kudela E; Kubatka P Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499265 [TBL] [Abstract][Full Text] [Related]
60. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas. MartÃn-Broto J; Moura DS; Van Tine BA Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]